PAR-25-270: NCCIH Natural Product Early Phase Clinical Trial Award (R33)

PAR-25-270: NCCIH Natural Product Early Phase Clinical Trial Award (R33)

Executive summary

The PAR-25-270 NOFO is a U.S. National Institutes of Health (NIH) funding opportunity administered by the National Center for Complementary and Integrative Health (NCCIH). It is explicitly for investigator-initiated, hypothesis-driven clinical trials of natural products such as botanicals, dietary supplements, probiotics, and standardized nutritional regimens.

This is not a broad translational or discovery grant. It is a preparatory clinical phase mechanism: projects must be designed to test target engagement in humans and then connect that mechanism to functional or clinical outcomes before a fully powered efficacy trial. In practical terms, this positions the mechanism as a gate for larger studies, not a final effectiveness confirmation study.

This opportunity is useful if your team already has credible pilot or preclinical evidence and can now generate stronger translational data through a registered clinical-trial-grade study. It is not intended to fund basic mechanistic work alone.

The NOFO is currently published with a clearly stated application due date of 2026-10-20 (5:00 PM local time of the applicant organization). The table also lists review milestones that run into 2027, so this is relevant for users targeting 2026/2027 planning windows.

At-a-glance details

What this opportunity funds (and what it does not fund)

What it funds

The NOFO is built for early phase clinical translation of natural products. The text repeatedly emphasizes that trials should:

• test a natural product or standardized nutritional regimen,
• confirm target engagement and mechanism-linked outcomes in humans,
• provide rationale for whether a larger efficacy program is warranted.

Typical project shape:

1. Use preliminary evidence to justify why a specific intervention deserves a trial.
2. Define a target and measurable engagement outcome.
3. Measure if and how engagement tracks with functional/clinical outcomes.
4. Show that the trial design can support go/no-go decisions for future larger trials.

The NOFO specifically notes this is a mechanism for work that is not yet an efficacy endpoint study, and it does not support broad clinical effectiveness studies.

What it does not fund

The NOFO is explicit about non-responsive cases:

• Animal-only studies.
• Studies without published peer-reviewed preliminary data demonstrating target engagement in humans.
• Applications that do not replicate target engagement and assess target-to-outcome association.
• Clinical trials that include synthetic derivatives or pro-drug style modifications of the natural product.
• Waitlist-control designs.
• Trials testing natural products for cancer prevention or treatment.

If your proposed study is efficacy-first or non-trial-based, the NOFO text indicates it will likely be considered out of scope. This is one of the strongest filters before writing.

Eligibility and organizational fit

This NOFO has a broad list of eligible U.S. applicants, including universities, nonprofits, for-profit entities (small business included), governments, and public/regional organizations.

Important disqualifier: non-domestic organizations are not eligible to apply. The page is clear that non-U.S. entities are not eligible, while foreign components of U.S.-based organizations may be allowed.

Who this is good for

This is a good fit if:

• your project is truly at early clinical trial stage and not purely preclinical,
• your product is clearly a natural product or standardized nutritional regimen,
• you can show a scientific rationale strong enough for R33-level scrutiny,
• you can recruit and retain participants with an operationally realistic feasibility plan,
• you have a team with clinical trials experience.

For small businesses and nonprofits, this can be a strong translational bridge because the mechanism is explicit, concrete, and bounded to what an R33 can responsibly support.

Who should consider alternatives instead

Not the right fit if your team is planning:

• broad proof-of-concept work without a clinical endpoint,
• efficacy/effectiveness trials as the primary objective,
• a cancer-focused natural product study (explicitly excluded here),
• purely conceptual research with weak implementation plan,
• applicants without ready access to a clinical operations infrastructure.

Key timelines and practical deadlines

From the official key-dates section, the opportunity lists 2026 due dates and review cycles and an expiration on 2026-11-14. The NOFO text includes multiple windows in earlier cycles and a regularized rhythm of dates across cycles.

For 2026/2027 planning, the practical anchor currently available is:

• Official due date: 2026-10-20.
• Time-of-day submission rule: 5:00 PM local time of applicant organization.
• Expiration date: 2026-11-14.

The NOFO also references future review windows (including March/May/July 2027 markers), so teams should treat this as an active cycle and a likely recurring opportunity if aligned to NIH standard windows.

Recommended backward-planning timeline

1. T-20 weeks: finalize the question, intervention, and primary target-engagement endpoint.
2. T-16 weeks: complete trial feasibility plan (subject availability, site capacity, retention strategy).
3. T-12 weeks: ensure registrations are active (SAM, eRA Commons, Grants.gov) and verify all profile identifiers match.
4. T-10 weeks: request protocol feedback from NCCIH scientific contacts if possible.
5. T-8 weeks: lock recruitment and monitoring plan, draft study record sections.
6. T-6 weeks: prepare budget tables and compliance sections (human subjects, clinical trials forms).
7. T-4 weeks: internal pre-submission technical check for formatting, page limits, mandatory attachments, and response deadlines.
8. T-1 week: dry-run submission in your electronic system and run post-validation.

Eligibility deep dive from the NOFO text

Eligible applicant entities

The official eligibility list is broad and includes:

• Higher education institutions (public/private),
• nonprofits including and excluding 501(c)(3) status,
• for-profit organizations and small businesses,
• state, county, city, district, tribal, and federal governments,
• independent school districts, housing authorities, faith/community organizations, and regional groups,
• U.S. territories/possessions (as eligible federal agency options).

The page is unusually strict on geography:

• Non-domestic entities: not eligible;
• Foreign components of eligible U.S. organizations: allowed.

This distinction matters for consortia with overseas collaborators. Partnering with a U.S. lead organization is not optional if non-U.S. entities want to participate.

Clinical trial requirement and content scope

A hard requirement in the NOFO is that only applications proposing clinical trials are accepted. The mechanism is R33 and the page repeatedly describes the intervention as early phase and exploratory with strict target engagement requirements.

Additional scope cues:

• The intervention must be a natural product with predefined standardized composition/rationale.
• The application should show how the project informs future larger clinical steps.
• R33s here are used to produce robust translational signals rather than final effectiveness claims.

Registration and submission prerequisites

The NOFO explicitly states all required registrations must be complete before submission and rejects late-registration excuses. It is also explicit about the consequences of incomplete registration compliance.

Required registrations include:

• System for Award Management (SAM), including active status and CAGE where required,
• eRA Commons,
• NIH/Grants.gov submission infrastructure as per NIH guidance,
• required eRA identifiers for all PD/PI profiles.

The page says registration can take six weeks or more, so teams should not assume they can complete this at the end.

Application process and required materials

The NOFO defines electronic submission pathways and the specific operational framework, and lists NIH ASSIST, institutional S2S with Grants.gov/eRA Commons, or Grants.gov Workspace.

Standard submission channels

1. NIH ASSIST (NIH-hosted submission and tracking),
2. Institutional systems-to-system with Grants.gov + eRA Commons,
3. Grants.gov Workspace with eRA Commons.

What you need to prepare (document expectations)

Your package is most likely judged on both science and implementation credibility. Focus your document build on:

• a protocol with a justified rationale for intervention and target,
• clearly defined recruitment and retention strategy,
• demonstrated availability of patient pool with evidence,
• explicit milestone logic linking phase findings to next-stage decisions,
• team qualifications and operational plan (clinical lead, biostatistics, trial operations, regulatory and data management readiness),
• strict compliance with NIH human subjects and clinical trial forms.

Optional but useful: Letter of intent

The NOFO describes an optional letter of intent template requiring title, PI details, key personnel, and participating institutions. Even though optional, many teams use it to pre-test organizational fit and reduce uncertainty.

Review criteria: how selection decisions are made

The reviewer lens is not generic and is explicitly tied to the mechanism’s purpose.

Scored criteria (high impact areas)

The review includes:

• significance/innovation,
• approach and rigor/feasibility,
• investigator(s) and environment.

For this NOFO, reviewers prioritize whether your study:

• is clearly justified as an early-phase step toward larger efficacy testing,
• demonstrates a strong rationale for outcome selection,
• has realistic sample size and feasible recruitment,
• has workable data collection and analysis plans,
• addresses biological variables and human subject protections,
• includes adequate trial infrastructure and resource commitments.

Reviewing teams also evaluate budget-period realism, environment feasibility, and whether your protocol is operational rather than aspirational.

What hurts in peer review

The NOFO includes specific indicators that can lower competitiveness:

• proposals framed around efficacy claims or cancer outcomes (explicitly excluded in scope),
• no robust preliminary target-engagement data,
• generic recruitment assumptions without participant access evidence,
• weak justification for IND/IDE or regulatory status if relevant,
• weak demonstration that the team can execute the required operations by budget and timeline.

Because the NOFO is clinical, non-operational proposals are the most common form of rejection.

Frequently asked questions

Is this only for rare diseases?

No. The eligibility text does not limit the opportunity to one disease class. The NOFO is disease-inclusive but insists on mission relevance and target-mechanism focus.

Can foreign teams apply directly?

No, non-domestic organizations are listed as ineligible. Foreign components may be included under U.S. organizations in some cases.

Is the $1,050,000 cap per year?

The cap is stated as the total direct-cost cap for the full award duration. The limit is not a per-year cap in the NOFO text available here.

Is there a required letter of intent?

No, it is optional and non-binding. Still, it can support pre-submission alignment for a complex trial program.

Can I use any submission route?

You must use one of the NIH-supported pathways: ASSIST, institutional S2S, or Grants.gov Workspace with required NIH/Commons registration.

Practical strategy checklist for a strong application

To turn this into a winning internal process, align your work to a few checks:

1) Confirm mechanism fit

Before writing, verify the study is naturally early phase and mechanistic enough for R33. If your team can only justify final endpoint claims, this may not fit.

2) Build operational proof early

A recurring issue in trial grants is a disconnect between science quality and trial feasibility. Include:

• candidate site capacity,
• recruitment sources and enrollment timeline,
• plans for retention and adverse event handling,
• staffing and monitoring responsibilities.

3) Make target engagement measurable

Define a primary biological or mechanism-linked endpoint and explain why it is the right bridge to future trials. This is the central promise of the NOFO.

4) Lock compliance documents early

Get regulatory status and registration dependencies out of your critical path:

• SAM/eRA/Grants.gov registration,
• PI credential requirements,
• required study record fields,
• human subjects and clinical trial forms.

5) Prepare a hard realism audit

Check your budget against actual protocol costs and timeline. NIH review looks closely at feasibility and period justification.

6) Test reviewers’ perspective

Ask three internal readers to score your draft for:

• clarity of R33 logic (not a full efficacy trial),
• participant recruitment credibility,
• how quickly reviewers can find what makes this trial unique and fundable.

Common mistakes and how to avoid them

Mistake: Submitting a trial that resembles efficacy work

The NOFO is explicit: this mechanism is exploratory and pre-efficacy decision support. If your proposal reads like a definitive efficacy phase, reviewers will likely mark a poor mechanism fit.

Mistake: Ignoring target engagement logic

The opportunity is built around measurable target engagement and association with outcomes. If this chain is weak, the core mechanism is compromised.

Mistake: Weak participant strategy

The NOFO expects evidence of feasibility in practice, including recruitment and retention planning. Vague statements like “participants can be recruited through clinics” are insufficient without method.

Mistake: Late/compliant registration errors

The NOFO states clearly: registrations must be complete before due date; there is little tolerance for incomplete electronic readiness.

Mistake: Underestimating data and safety obligations

Clinical-trial submissions are judged on practical rigor and participant safety architecture. The NOFO includes human subjects and trial-specific requirements that should be explicit and complete.

Common review questions you should answer in plain language

Reviewers are not just asking “is this an interesting idea?” They ask:

1. Can this produce actionable evidence in one funding period?
2. Is there enough feasibility to recruit and retain participants?
3. Is the design robust enough to support progression decisions?
4. Does the team have enough trial-operational maturity?
5. Can budget and timeline support completion?

If you can answer yes to each, your proposal is in the right lane for this NOFO.

Applicant action plan after reading this page

1. Read the full NOFO once from top to bottom before drafting.
2. Confirm your intervention is not out-of-scope (no cancer treatment/prevention under this NOFO).
3. Draft your scientific rationale around target engagement, not broad exploratory speculation.
4. Build a feasibility annex with site data and recruitment evidence.
5. Start registrations immediately and verify identifiers across SAM/eRA/Grants.gov.
6. Prepare both primary and backup submission bundles.
7. Submit with buffer for technical validation.

Official links and references

• Official NOFO: https://www.grants.nih.gov/grants/guide/pa-files/PAR-25-270.html
• NIH How to Apply guidance: https://grants.nih.gov/grants/how-to-apply
• NIH Grants Policy Statement (policy and compliance): https://grants.nih.gov/grants/guide/notice-files
• NCCIH program contact listed on NOFO: Jessica McKlveen, Ph.D.

If you are preparing a submission within this window, treat this as a trial-readiness check and not a generic grant-writing exercise. The program rewards teams that can prove mechanism-to-next-step value with operational credibility.